University of Texas Health Sciences Center at San Antonio, 78229, USA.
Cancer Prev Res (Phila). 2010 Jun;3(6):686-8. doi: 10.1158/1940-6207.CAPR-10-0100.
This perspective on Vogel et al. (beginning on page 696 in this issue of the journal) examines tamoxifen and raloxifene prescription patterns and why these agents are little used for breast cancer prevention despite their effectiveness in definitive trials, Food and Drug Administration approval, and American Society of Clinical Oncology Guidelines Committee endorsement for this purpose. The complexity of weighing the positive and negative aspects of the drugs and estimating net benefit is discussed, as is the need for informational resources such as interactive Internet-based tools to allow better individualized decisions about the options for chemoprevention.
这篇观点文章（本期杂志第 696 页开始）探讨了他莫昔芬和雷洛昔芬的处方模式，以及尽管这些药物在明确的临床试验、美国食品和药物管理局批准以及美国临床肿瘤学会指南委员会为此目的的认可中显示出有效性，但为什么它们在乳腺癌预防中的应用很少。文章讨论了权衡药物的积极和消极方面以及估计净效益的复杂性，以及需要信息资源，如交互式互联网工具，以允许更好地对化学预防的选择做出个体化决策。
